1. Home
  2. STELLA PHARMA NEWS
STELLA PHARMA NEWS
December 10th, 2024

Observation Period Completed for Primary Endpoint – Phase II Clinical Trial in Patients with Angiosarcoma

We are pleased to announce the completion of the 90-day observation period for ……

READ MORE

December 6th, 2024

Paper published: Poly(vinyl alcohol) Potentiating an Inert D-Amino Acid-Based Drug for Boron Neutron Capture Therapy

The paper titled “Poly(vinyl alcohol) potentiating an inert D-amino acid-based ……

READ MORE

November 20th, 2024

Paper published: Research on Combination of Proton Beam Therapy and Boron Nuclear Capture Reaction

The Paper titled “Increased cell killing effect in neutron capture enhanced pro……

READ MORE

November 14th, 2024

Announcement of Agreement Conclusion with TAE LIFE SCIENCES for Collaboration in the Development and Commercialization of BPA Drug for BNCT in Europe and the US

STELLA PHARMA CORPORATION announced today that our Company has entered into a D……

READ MORE

September 25th, 2024

Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma

Our product Borofalan (10B) (development code: SPM-011), which we are developin……

READ MORE

September 10th, 2024

Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma

Stella Pharma completed the enrollment of patients for the domestic phase II do……

READ MORE

September 6th, 2024

Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT

Stella Pharma announces that it has signed an agreement with the National Cance……

READ MORE

August 30th, 2024

Paper published: Research on Combination Therapy of BNCT and Immune Checkpoint Inhibitors

The Paper “Overcoming immunotherapy resistance and inducing abscopal effects wi……

READ MORE

August 30th, 2024

Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma

Stella Pharma announces that it has applied to the Japanese Ministry of Health,……

READ MORE

July 16th, 2024

Specified Clinical Research Contract concluded with Edogawa Hospital

― Providing our drug for Research on FDG-PET-positive shallow tumors ― Stell……

READ MORE

July 10th, 2024

Safety and Efficacy of BNCT: paper in “Radiotherapy and Oncology” 

The paper “Efficacy and safety of boron neutron capture therapy for Hypopharyng……

READ MORE

June 24th, 2024

BNCT for Thoracic Malignant Tumor – Submission of Trial Plan Notification for Domestic Clinical Trial Phase I/II

We would like to announce that our company submitted the trial plan notificatio……

READ MORE